United Kingdom - English - MHRA (Medicines & Healthcare Products Regulatory Agency)

esteve pharmaceuticals ltd - gonadorelin hydrochloride - powder and solvent for solution for injection - 100microgram

Canada - English - Health Canada

pfizer canada ulc - nafarelin (nafarelin acetate) - metered-dose aerosol - 200mcg - nafarelin (nafarelin acetate) 200mcg - gonadotropins and antigonadotropins

Canada - English - Health Canada

modern veterinary therapeutics llc - gonadorelin [6-d-phe] acetate - solution - 54mcg - gonadorelin [6-d-phe] acetate 54mcg - cattle

United States - English - NLM (National Library of Medicine)

emd serono, inc. - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 250 ug in 0.5 ml - ovidrel® prefilled syringe (choriogonadotropin alfa injection) is indicated for the induction of final follicular maturation and early luteinization in infertile women who have undergone pituitary desensitization and who have been appropriately pretreated with follicle stimulating hormones as part of an assisted reproductive technology (art) program such as in vitro fertilization and embryo transfer. ovidrel® prefilled syringe is also indicated for the induction of ovulation (oi) and pregnancy in anovulatory infertile patients in whom the cause of infertility is functional and not due to primary ovarian failure. - before treatment with gonadotropins is instituted, a thorough gynecologic and endocrinologic evaluation must be performed. this should include an assessment of pelvic anatomy. patients with tubal obstruction should receive ovidrel® prefilled syringe only if enrolled in an in vitro fertilization program. - primary ovarian failure should be excluded by the determination of gonadotropin levels. - appropriate evaluation should be performed to exclude pregnancy. - patients in later reproductive life have a greater predisposition to endometrial carcinoma as well as a higher incidence of anovulatory disorders. a thorough diagnostic evaluation should always be performed in patients who demonstrate abnormal uterine bleeding or other signs of endometrial abnormalities before starting fsh and ovidrel® prefilled syringe therapy. - evaluation of the partner's fertility potential should be included in the initial evaluation. ovidrel® prefilled syringe (choriogonadotropin alfa injection) is contraindicated in women who exhibit: - prior hypersensitivity to hcg preparations or one of their excipients. - primary ovarian failure. - uncontrolled thyroid or adrenal dysfunction. - an uncontrolled organic intracranial lesion such as a pituitary tumor. - abnormal uterine bleeding of undetermined origin (see "selection of patients" ). - ovarian cyst or enlargement of undetermined origin (see "selection of patients" ). - sex hormone dependent tumors of the reproductive tract and accessory organs. - pregnancy.

United States - English - NLM (National Library of Medicine)

fresenius kabi usa, llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity.  there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or ‘‘normal’’ distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction.  in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty.  hcg thus may help predict whether or not orchiopexy will be needed in the future.  although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary.  therapy is usually instituted between the ages four and nine. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovulati

United States - English - NLM (National Library of Medicine)

western chemical inc. - salmon gonadotropin releasing hormone d-arg6 analog ethyl amide acetate (unii: 66kw0e903i) (salmon gonadotropin releasing hormone d-arg6 analog ethyl amide - unii:whi058yg4q), domperidone (unii: 5587267z69) (domperidone - unii:5587267z69) - salmon gonadotropin releasing hormone d-arg6 analog ethyl amide 20 ug in 1 ml - note---in order to be legally marketed, an animal drug product intended for a minor species must be approved, conditionally approved, or indexed by the fda. this product is indexed. it is a violation of federal law to use this product in a manner other than as directed in the labeling. as used on this label, the words “ornamental fish” refer to a wide variety of finfish species maintained primarily for their appearance and do not include any fish that are consumed by humans or food-producing animals. net contents: 10 ml description: ovaprim® is a liquid peptide preparation that contains an analog of salmon gonadotropin releasing hormone (sgnrha) and a brain neurotransmitter (dopamine) inhibitor. the sgnrha in ovaprim® elicits the release of stored gonadotropins from the pituitary. the dopamine inhibitor (domperidone) serves to remove other inhibition of gnrh release. release of stored pituitary gonadotropins may aid spawning by stimulating ovulation and spermiation in sexually mature fish. indication: for

United States - English - NLM (National Library of Medicine)

merck sharp & dohme llc - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent, in most cases, the response is temporary. therapy is usually instituted in children between the ages of 4 and 9. - selected cases of hypogonadotropic hypogonadism (hypogonadism secondary to a pituitary deficiency) in males. - induction of ovulation and pregnancy in the anovulatory, infertile woman in whom the cause of anovula

United States - English - NLM (National Library of Medicine)

physicians total care, inc. - choriogonadotropin alfa (unii: 6413w06wr3) (choriogonadotropin alfa - unii:6413w06wr3) - choriogonadotropin alfa 10000 [usp'u] in 10 ml - hcg has not been demonstrated to be effective adjunctive therapy in the treatment of obesity. there is no substantial evidence that it increases weight loss beyond that resulting from caloric restriction, that it causes a more attractive or “normal” distribution of fat, or that it decreases the hunger and discomfort associated with calorie-restricted diets. - prepubertal cryptorchidism not due to anatomical obstruction. in general, hcg is thought to induce testicular descent in situations when descent would have occurred at puberty. hcg thus may help predict whether or not orchiopexy will be needed in the future. although, in some cases, descent following hcg administration is permanent,

Israel - English - Ministry of Health

merck serono ltd - choriogonadotropin alfa - solution for injection - choriogonadotropin alfa 250 mcg / 0.5 ml - choriogonadotropin alfa - choriogonadotropin alfa - - for women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilization (ivf) : ovitrelle is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. - anovulatory or oligo-ovulatory women: ovitrelle is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.

Australia - English - Department of Health (Therapeutic Goods Administration)

merck healthcare pty ltd - choriogonadotropin alfa, quantity: 250 microgram - injection, solution - excipient ingredients: mannitol; water for injections; methionine; dibasic sodium phosphate dihydrate; poloxamer; phosphoric acid; sodium hydroxide; monobasic sodium phosphate monohydrate - ovidrel is indicated in the treatment of (i) women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (ivf): ovidrel is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth. (ii) anovulatory or oligo-ovulatory women: ovidrel is administered to trigger ovulation and luteinisation in anovulatory or oligo-ovulatory patients after stimulation of follicular growth.